Vertex Sells Legacy Oncology Portfolio To German Merck
Executive Summary
Vertex Pharmaceuticals has sold off its oncology portfolio, comprised of six molecules across four early stage programs, to Merck of Germany for $230m and future royalties on sales – a low price tag in the immune-oncology deal spree arena.
You may also be interested in...
Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner
The German group has been laying out its future plans to investors, which include reducing debt and a strong revenue stream from its Pfizer-partnered checkpoint inhibitor Bavencio.
Deal Watch: J.P. Morgan Brings Continued Brisk Pace Of Transactions
Allergan strikes a pair of deals for gastrointestinal and CNS candidates, while Amgen expands its reach in bispecific antibodies via a partnership with Immatics.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.